EXEL vs TECH: fair value comparison
Exelixis, Inc. and Bio-Techne Corporation · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EXEL currently sits closer to the top of our discount ranking.
| EXEL | TECH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $55.06 | $72.43 |
| 12-month range | $38.06–$55.06 | $50.79–$72.18 |
| Sector rank | #46 of 113 Healthcare | #49 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: EXEL fair value analysis · TECH fair value analysis